Proteins

Yamogenin

Cat. No.: HY-N2078 CAS No.: 512-06-1 Molecular Formula: C₂₇H₄₂O₃ Molecular Weight: 414.62 Target: LXR

Pathway: Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Storage: Powder -20°C 3 years

In solvent

4°C 2 years -80°C 6 months

-20°C 1 month

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

Ethanol: 1 mg/mL (2.41 mM; Need ultrasonic and warming)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.4118 mL	12.0592 mL	24.1185 mL
	5 mM			
	10 mM			

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% EtOH >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1 mg/mL (2.41 mM); Clear solution
- 2. Add each solvent one by one: 10% EtOH >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1 mg/mL (2.41 mM); Clear solution
- 3. Add each solvent one by one: 10% EtOH >> 90% corn oil Solubility: ≥ 1 mg/mL (2.41 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin (Neodiosgenin) antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin (Neodiosgenin) inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes ^[1] .
IC ₅₀ & Target	IC50: TG accumulation; liver X receptor (LXR) ^[1]

Moriwaki S. et al. Vamo	ogenin in fenugreek inhibits linid accu	mulation through the supp	ression of gene expression in fatty acid synthe	sis in hanatocytos Riosci
echnol Biochem. 2014		mutation through the supp	ession of gene expression in fatty acid synthe	sis in nepatocytes.Biosci
			edical applications. For research use onl	
	Tel: 609-228-6898 Address: 1 Dee	Fax: 609-228-5909 er Park Dr, Suite Q, Monm	E-mail: tech@MedChemExpress.com outh Junction, NJ 08852, USA	II

Page 2 of 2 www.MedChemExpress.com